Drug intelligence / Profile preview

LYP-010

Development stage: Preclinical
Lead developer: Lypanosys
Modality: Small Molecules
Administration: Oral

Overview

LYP-010 is an oral small molecule immunity-modulating drug being developed by WEIR Science for the treatment of eczema. The compound was developed by Dr. Iona Weir using the proprietary Myrecil platform, which focuses on identifying and optimizing bioactive compounds for therapeutic use. LYP-010 is designed to modulate immune pathways involved in the pathogenesis of atopic dermatitis, though its specific molecular targets have not been publicly disclosed. It is positioned as a pharmaceutical intervention within the company's pipeline of immunity-focused therapies.

Beyond the preview

Go deeper on LYP-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYP-010.

Explore the full profile